Structured facts
{
"code": "C",
"date": "2026-06-15",
"direction": "D",
"exercise_price": null,
"expiration": null,
"footnotes": {
"F1": "Subject to certain conditions set forth in the Certificate of Designation of Preferences, Rights and Limitations of the Series B Preferred Stock, each share of Series B Preferred Stock is convertible into 1,000 shares of the Issuer\u0027s Common Stock and has no expiration date.",
"F2": "Pursuant to February 17, 2026 Agreement and Plan of Merger (the \"Merger Agreement\"), by and among the Issuer, Sapphire First Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Issuer (\"First Merger Sub\"), Sapphire Second Merger Sub, LLC, a Delaware limited liability company and wholly owned subsidiary of the Issuer (\"Second Merger Sub\"), Faeth Holdings Therapeutics, Inc. (\"HoldCo\") and Faeth Therapeutics, LLC, a Delaware limited liability company and wholly owned subsidiary of HoldCo (\"Faeth\"), First Merger Sub merged with and into HoldCo, with HoldCo surviving the first merger as a wholly owned subsidiary of the Issuer, and immediately following the first merger, HoldCo merged with and into Second Merger Sub, with Second Merger Sub surviving the second merger as a wholly owned subsidiary of the Issuer (such mergers, the \"Merger\").",
"F3": "Footnote continued: Upon the closing of the Merger, shares of outstanding common stock of HoldCo were converted into the right to receive shares of the Issuer\u0027s Series B Preferred Stock."
},
"owners": [
{
"cik": "0002137706",
"name": "Hahn Stephen M.",
"roles": [
"director"
],
"title": null
}
],
"ownership": "D",
"post_shares": "0",
"price": null,
"row": 2,
"rule_10b5_1": "0",
"security": "Series B Preferred Stock",
"shares": "44.763",
"table": "II",
"underlying_security": "Common Stock",
"underlying_shares": "44763"
}